ArticleWorld journal of microbiology & biotechnology2013
Identification of non-TAL effectors in Xanthomonas oryzae pv. oryzae Chinese strain 13751 and analysis of their role in the bacterial virulence.
Article in World journal of microbiology & biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Identification of protein secretion systems and type III effectors in wood-associated bacteria of the genusMicrobiology spectrum · 2026Article
- Effectidor II: a pan-genomic AI-based algorithm for the prediction of type III secretion system effectors.Bioinformatics (Oxford, England) · 2025Article
- Arms and ammunitions: effectors at the interface of rice and it's pathogens and pests.Rice (New York, N.Y.) · 2021Review
- Tal1Frontiers in microbiology · 2019Article
- Effector GeneJournal of bacteriology · 2018Article
- Non-TAL Effectors FromFrontiers in plant science · 2018Article
- Complete Genome Sequencing and Targeted Mutagenesis Reveal Virulence Contributions of Tal2 and Tal4b ofFrontiers in microbiology · 2017Article
- The genome of the cotton bacterial blight pathogenStandards in genomic sciences · 2017Article
- Article
- Xanthomonas oryzae pv. oryzae type III effector XopN targets OsVOZ2 and a putative thiamine synthase as a virulence factor in rice.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xanthomonas oryzae pv. oryzae (Xoo) is the causal agent of rice bacterial leaf blight, one of the most important rice bacterial diseases in China and many other countries. The upstream portions of 41 candidate genes encoding non-transcription activator-like effectors of Xoo Chinese strain 13751 were fused with the coding sequence of AvrBs159-445 in a broad host-range vector. The constructed plasmids were respectively introduced into Xoo strain 13751 and avrBs1 deletion mutant of X. campestris pv. campestris strain 8004 by tri-parental conjugation. The resultant transconjugants were respectively tested for hypersensitive response (HR) elicitation on pepper ECW-10R. Nine strains were able to elicit HR on pepper, indicating that the nine genes (XOO0037, XOO0103, XOO0110, XOO0315, XOO1488, XOO2875, XOO3150, XOO3222 and XOO4134) encoded effectors. Among them, xopAE 13751 (XOO0110), expressed in Xoo strain 13751 growing in rice leaves, was a new experimentally confirmed effector gene. XopAE13751 contains 11 leucine rich repeats. Furthermore, mutants for the nine effector genes were created in Xoo strain 13751 and subsequently tested for virulence in rice. As a result, only the xopR 13751 (XOO4134) deletion mutant GXMxopR showed a significant reduction in virulence in hybrid rice cv. Teyou63 compared to the wild type. However, the growth of GXMxopR in host plant rice was not affected. These results indicated that xopR 13751 was required for full virulence of Xoo strain 13751 by inducing rice disease tolerance.
Indexed as
Identifiers
23296915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.